首页
探索
nav.journalClub
趋势
更多
synapse
⌘+K
语言
简体中文
简体中文
Sustained Survival after Cord Blood Transplantation without Serotherapy in Pediatric Congenital Disorders | Synapse
March 3, 2026
Sustained Survival after Cord Blood Transplantation without Serotherapy in Pediatric Congenital Disorders
EU
Erin Morales Ubico
JF
Josaura Fernandez
ED
Erin Doherty
Baylor College of Medicine
See all
Key Points
Sustained survival after cord blood transplantation highlights the potential of hematopoietic stem cells for treating congenital disorders.
Overall survival rates improved notably without the use of serotherapy, emphasizing a promising approach for pediatric patients.
This analysis involved the assessment of pediatric patients who underwent cord blood transplantation, focusing on clinical outcomes.
Findings imply that avoiding serotherapy may enhance treatment effectiveness in specific pediatric congenital conditions.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Ubico et al. (Sun,) studied this question.
synapsesocial.com/papers/69a75ffec6e9836116a2c602
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.175